

# Tara A Russell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4268843/publications.pdf>

Version: 2024-02-01

46  
papers

1,375  
citations

279798

23  
h-index

330143

37  
g-index

46  
all docs

46  
docs citations

46  
times ranked

743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative Measure of Intestinal Permeability Using Blue Food Coloring. <i>Journal of Surgical Research</i> , 2019, 233, 20-25.	1.6	4
2	Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Journal of Drug Targeting</i> , 2019, 27, 211-216.	4.4	11
3	Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019, 58, 107-111.	2.2	3
4	Assessment of Anastomotic Biliary Complications in Adult Patients Undergoing High-Acuity Liver Transplant. <i>JAMA Surgery</i> , 2019, 154, 431.	4.3	22
5	Minimizing central line-associated bloodstream infections in a high-acuity liver transplant intensive care unit. <i>American Journal of Infection Control</i> , 2019, 47, 305-312.	2.3	8
6	Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cell Cycle</i> , 2018, 17, 722-727.	2.6	9
7	Tumor-targeting <i>Salmonella typhimurium</i> A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1055-1061.	2.1	28
8	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with recombinant methioninase and cisplatin eradicates an osteosarcoma cisplatin-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. <i>Cell Cycle</i> , 2018, 17, 801-809.	2.6	57
9	Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. <i>Cell Cycle</i> , 2018, 17, 627-633.	2.6	13
10	Rescue Diverting Loop Ileostomy: An Alternative to Emergent Colectomy in the Setting of Severe Acute Refractory IBD-Colitis. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 214-220.	1.3	16
11	Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. <i>Cancer Letters</i> , 2018, 417, 168-173.	7.2	56
12	Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. <i>Cell Cycle</i> , 2018, 17, 356-361.	2.6	40
13	Growth of doxorubicin-resistant undifferentiated spindle cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3537-3544.	2.6	30
14	<i>Sustaining Improvement: Implementation and Spread of a Surgical Site Infection Bundle</i> . <i>American Surgeon</i> , 2018, 84, 1665-1669.	0.8	4
15	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 912-917.	2.1	29
16	A combination of irinotecan/cisplatin and irinotecan/temozolomide or tumor-targeting <i>Salmonella typhimurium</i> A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 733-739.	2.1	18
17	Tumor-targeting <i>Salmonella typhimurium</i> A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP). <i>Tissue and Cell</i> , 2018, 54, 144-149.	2.2	8
18	Combination therapy of tumor-targeting <i>Salmonella typhimurium</i> A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 3086-3092.	2.1	27

#	ARTICLE	IF	CITATIONS
19	Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 7827-7833.	2.6	6
20	Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 12.	17.1	5
21	Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision oncology nude mouse model matching the patient with effective therapy. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6598-6603.	2.6	14
22	Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2018, 53, 30-36.	2.2	18
23	Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>BMC Cancer</i> , 2018, 18, 840.	2.6	14
24	Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. <i>Heliyon</i> , 2018, 4, e00643.	3.2	11
25	Temozolomide combined with irinotecan regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. <i>Oncotarget</i> , 2018, 9, 7774-7781.	1.8	22
26	Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. <i>Oncotarget</i> , 2018, 9, 915-923.	1.8	42
27	Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Oncotarget</i> , 2018, 9, 11119-11125.	1.8	35
28	Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2018, 9, 19263-19272.	1.8	22
29	Sustaining Improvement: Implementation and Spread of a Surgical Site Infection Bundle. <i>American Surgeon</i> , 2018, 84, 1665-1669.	0.8	3
30	Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2314-2319.	2.6	53
31	Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. <i>Cell Cycle</i> , 2017, 16, 1063-1069.	2.6	30
32	Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Cell Cycle</i> , 2017, 16, 1164-1170.	2.6	49
33	Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , 2017, 16, 1288-1294.	2.6	37
34	Distinction of Risk Factors for Superficial vs Organ-Space Surgical Site Infections After Pancreatic Surgery. <i>JAMA Surgery</i> , 2017, 152, 1023.	4.3	36
35	Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 361-365.	2.6	34
36	Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. <i>Oncotarget</i> , 2017, 8, 8035-8042.	1.8	50

#	ARTICLE	IF	CITATIONS
37	Optimizing the Management of Abnormal Liver Function Tests after Orthotopic Liver Transplant: A Systems-Based Analysis of Health Care Utilization. <i>American Surgeon</i> , 2017, 83, 1152-1156.	0.8	3
38	Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	3.0	5
39	A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. <i>Oncotarget</i> , 2017, 8, 62111-62119.	1.8	48
40	Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2017, 8, 85516-85525.	1.8	67
41	The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and <i>CDKN2A</i> deletion: Direction for third-line patient therapy. <i>Oncotarget</i> , 2017, 8, 103129-103136.	1.8	38
42	Optimizing the Management of Abnormal Liver Function Tests after Orthotopic Liver Transplant: A Systems-Based Analysis of Health Care Utilization. <i>American Surgeon</i> , 2017, 83, 1152-1156.	0.8	1
43	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2016, 7, 71737-71743.	1.8	72
44	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016, 7, 85929-85936.	1.8	77
45	Tumor-targeting <i>Salmonella typhimurium</i> A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016, 7, 12783-12790.	1.8	109
46	Effective molecular targeting of CDK4/6 and IGF-1R in a rare <i>FUS-ERG</i> fusion <i>CDKN2A</i> -deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2016, 7, 47556-47564.	1.8	91